Central Sensitization Symptoms and Psychosocial Factors in Athletes After ACL Reconstruction
CompletedNCT04393129
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The main research objective of this study is whether athletes who have sustained an anterior cruciate ligament injury, experience chronic nociplastic pain and psychosocial factors, including kinesiophobia and pain catastrophizing, after having been through ACL reconstruction surgery and rehabilitation and have returned to sport.
Study details
- Official title
- Prevalence of Central Sensitization Symptoms and Psychosocial Factors in Athletes After ACL Reconstruction and Return to Play
- Conditions
- Anterior Cruciate Ligament Rupture
- Sponsor
- University of Thessaly
- Collaborators
- KAT General Hospital
- Start date
- 2019-10-01
- Primary completion
- 2020-02-27
- Sex
- All
- Age range
- from 18 Years to 45 Years
- Results posted
- No results posted in this snapshot
- Countries
- Greece
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. knowledge of Greek language, 2. surgically reconstructed ACL tear on one limb only, 3. successful completion of rehabilitation program, 4. medical permission to return to sport, 5. returned to previous sport for at least 6 months period 6. athlete of a lower limb loading sport. Exclusion Criteria: 1. adolescent age (\<18 years of age), 2. diagnosis of cancer of any stage, 3. diagnosis of psychiatric, neurological or autoimmune disease or syndrome, 4. past musculoskeletal injuries, including fractures, joints dislocation, ligament and tendon tears and 5. chronic musculoskeletal injuries (tendinopathies, shin splints, shoulder impingement etc.). Chronic pain is defined as pain persisting for at least 3 months, of intensity at least 3 on the VAS scale for most days per week (Kuppens et al. 2018).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04393129